Molecular cytogenetics involves every aspect of chromosome biology and the application of this technique in all areas of medicine and biology, including functional and structural organization of the nucleus and chromosomes, expression and evolution, chromosome abnormalities in tumor genetics and medical genetics, and genome variation. This branch of science uses technologies like karyotyping, immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH) to detect various chromosomal and genetic aberrations. These techniques are used for the construction of molecular, genetic, comparative, and physical maps.
The market generated revenue of $1.8 billion in 2017, and it is projected to reach $3.3 billion by 2023. Moreover, an increase in the cancer research activities will facilitate the market growth in the foreseeable future, as researchers are using CGH and FISH to gain critical information about cancer-related molecular signatures.
Currently, a surge in the mergers and acquisitions among key players like Agilent Technologies Inc., NeoGenomics Inc., Danaher Corporation, Bio-Rad Laboratories Inc., Abbott Laboratories, PerkinElmer Inc., Illumina Inc., and F. Hoffmann La-Roche AG is being witnessed. For instance, Agilent Technologies Inc. acquired Advanced Analytical Technologies Inc., a capillary electrophoresis-based (CE) solution provider for complete automated analysis of a range of molecules, in March 2018. Through this acquisition, Agilent Technologies Inc. enhanced its expertise and technology to provide consumers with a more-comprehensive solution.
Get More Information about the Molecular Cytogenetics Market Report
According to P&S Intelligence, the Asia-Pacific (APAC) region will exhibit the fastest growth in the usage of molecular cytogenetics techniques in the foreseeable future, due to the vast population, unmet need for cancer diagnosis and treatment, and entry of global pharmaceutical and biotechnology companies providing cytogenetic testing in the region. As per the World Health Organization (WHO), “Approximately 70% of deaths from cancer occur in low- and middle-income countries.” Moreover, the escalating healthcare spending and advancing healthcare system will accelerate the adoption of molecular cytogenetic techniques.
Thus, the rising number of cancer cases will fuel the adoption of molecular cytogenetics techniques for diagnosis and treatment purposes in the coming years.
This study covers
• Major factors driving the market and their impact during the short, medium, and long terms
• Market restraints and their impact during the short, medium, and long terms
• Recent trends and evolving opportunities for the market participants
• Historical and the present size of the market segments and understand their comparative future potential
• Potential of on-demand logistics services, so the market players make informed decisions on the sales of their offerings
• Competitive scenario of various market segments across key countries in several regions for uncovering market opportunities for the stakeholders
• Major players operating in the market and their service offerings
The Molecular Cytogenetics Market is projected to reach USD 2.52 Billion, at a CAGR of 10.1%.According to the new market research report "Molecular Cytogenetics Market by Product (Kit, Reagent, Probe, Consumable, Software, Service), Technique (In-Situ, FISH, Comparative Genomic Hybridization), Application (Cancer, Genetic), End User (Research Labs, Institutes) - Forecast to 2021" , published by MarketsandMarkets™, report provides a detailed overview of the major drivers, restraints, challenges, opportunities, and strategies impacting the molecular cytogenetics market along with the estimates and forecasts of the revenue and market share analysis.The major factors driving the growth of this market are increasing incidence of genetic disorders and cancer, rapid growth in the aging population, and growing healthcare expenditure worldwide.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224 The objectives of this study are as follows: To define, describe, and forecast the global molecular cytogenetics market by product, technique, application, end user, and regionTo provide detailed information regarding the major factors influencing market growth (drivers, restraints, and opportunities)To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall molecular cytogenetics marketTo analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leadersTo forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)Browse and in-depth TOC on " Molecular Cytogenetics Market " 157 - Tables76 - Figures 212 - Pages On the basis of techniques, the molecular cytogenetics market is segmented into comparative genomic hybridization, fluorescence in situ hybridization, in situ hybridization, and other techniques.Based on applications, the molecular cytogenetics market is segmented into genetic disorders, cancer, personalized medicine, and other applications.
The genetic disorders segment is expected to account for the largest share of the global molecular cytogenetics market in 2016.Based on regions, the global molecular cytogenetics market is segmented into North America, Europe, Asia, and the Rest of the World (RoW).
North America is expected to account for the largest share of the market during the forecast period.
Growth in this regional segment is driven by factors such as increase in the aging population and increasing prevalence of cancer and genetic disorders in the region.Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsample.asp?id=148469224 Key players in the molecular cytogenetics market include F. Hoffmann-La Roche Ltd. (Switzerland) Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), PerkinElmer, Inc. (U.S.), Illumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Gene Technology (U.K.), and Applied Spectral Imaging (U.S.).
